New treatments

This page will list articles and news about new cancer treatments approved in Canada.

Health Canada Approves XTANDI® (enzalutamide) – the First and Only Oral Treatment for Men with Non-Metastatic and Metastatic Castration-Resistant Prostate Cancer (January 2019)

AGRISSO received a positive final recommendationfor listing from pCODR supporting the significant clinical benefits of TAGRISSO (osimertinib) for the first-line (1L) treatment of patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) whose tumours have epidermal growth receptor (EGFR) mutations (exon 19 deletions or exon 21 [L858R]) (January 2019)

Novartis receives Health Canada approval for the combination therapy of Tafinlar® (dabrafenib) plus Mekinist® (trametinib) for adjuvant treatment of patients with BRAF V600 mutation melanoma(i) (November 2018)

Health Canada approves PERJETA® (pertuzumab) for the treatment of HER2-positive early breast cancer after surgery (September 2018)

Health Canada Approves Tagrisso® (osimertinib) as First-line Treatment for EGFR-Mutated Non-Small Cell Lung Cancer (July 2018)

Only Immuno-Oncology Combination Therapy Approved by Health Canada as First-Line Treatment for Advanced or Metastatic Renal Cell Carcinoma (July 2018)

Health Canada Approves GAZYVA® for Previously Untreated Advanced Follicular Lymphoma (July 2018)

Health Canada Approves ERLEADA™* (apalutamide tablets), the First Treatment for Men with Non-Metastatic Castration-Resistant Prostate Cancer (July 2018)

ALECENSARO® (alectinib) approved by Health Canada for first-line treatment of ALK-positive lung cancer (June 2018)

Lynparza® (olaparib) Receives New Indication for BRCA-Mutated Metastatic Breast Cancer (May 2018)

First and Only Immuno-Oncology Treatment, Imfinzi® (durvalumab), for Stage III, Unresectable Non-Small Cell Lung Cancer Now Approved in Canada (May 2018)

Lynparza® (olaparib) tablets receive approval as maintenance therapy treatment for ovarian cancer regardless of BRCA status (May 2018)

Health Canada approves KISQALI™ for the treatment of HR-positive and HER2-negative metastatic breast cancer in postmenopausal women in combination with letrozole as an initial endocrine-based therapy (May 2018)

Health Canada approves TECENTRIQ® (atezolizumab) for the treatment of patients with metastatic non-small cell lung cancer (April 2018)

Health Canada Approves RITUXAN® Subcutaneous Formulation for Canadians with Chronic Lymphocytic Leukemia (March 2018)

Taiho Pharma Canada, Inc. announces Health Canada approval of LONSURF® (trifluridine and tipiracil tablets) for metastatic colorectal cancer (March 2018)